|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?显示文摘In resectable colorectal liver metastasis(CRLM) the role and use of molecular biomarkers is still controversial. Several biomarkers have been linked to clinical outcomes in CRLM, but none have so far become routine for clinical decision making. For several reasons, the clinical risk score appears to no longer hold the same predictive value. Some of the reasons include the ever expanding indications for liver resection, which now increasingly tend to involve extrahepatic disease, such as lung metastases(both resectable and non-resectable) and the shift in indication from 'what is taken out'(e.g., how much liver has to be resected) to 'what is left behind'(that is, how much functional liver tissue the patient has after resection). The latter is amenable to modifications by using adjunct techniques of portal vein embolization and the associating liver partition and portal vein ligation for staged hepatectomy techniques to expand indications for liver resection. Added to this complexity is the increasing number of molecular markers, which appear to hold important prognostic and predictive information, for which some will be discussed here. Beyond characteristics of tissue-based genomic profiles will be liquid biopsies derived from circulating tumor cells and cell-free circulating tumor DNA in the blood. These markers are present in the peripheral circulation in the majority of patients with metastatic cancer disease. Circulating biomarkers may represent more readily available methods to monitor, characterize and predict cancer biology with future implications for cancer care. | Torhild Veen Kjetil Soreide | 2017 | World Journal of Gastrointestinal Oncology2017，9，3： | 4 |
| 2 | Physical Self-Concept and Sports: Do Gender Differences Still Exist?显示文摘 | Anne Torhild Klomsten Einar M. Skaalvik Geir Arild Espnes | 2004 | Sex Roles (-)2004，，1： | 1 |
| 3 | Dietary intake of advanced glycation endproducts(AGEs)and cancer risk across more than 20 anatomical sites:A multinational cohort study显示文摘Dear Editor,In the European region,which shares 22.8%of the global cancer burden for 10%of the global population,there were around 4.4 million new cancer cases and 1.9 million deaths from cancer in 2020[1].The reasons for the high cancer incidence rates are complex;however,diet and dietary components are among the main contributors to cancer risk[2].In modern-day living,a growing proportion of people include in their diets ultra-processed foods.Byproducts of food processing and home-prepared foods are so-called dietary advanced glycation endproducts(AGEs),which are reactive metabolites emerging during the breakdown of reducing sugar.AGEs production is preponderant in dry high-heat processes(e.g.,baking,roasting);hence foods such as cakes,crisps,crackers,cereal products,meat and meat-derived products represent a major source of dietary AGEs[3]. | Reynalda Córdova Ana-Lucia Mayén Viktoria Knaze Elom Kouassivi Aglago Casper Schalkwijk Karl-Heinz Wagner Kim Overvad Anne Tjønneland Cecilie Kyrø Verena Andrea Katzke Charlotte Le Cornet Matthias Bernd Schulze Anna Birukov Domenico Palli Sara Grioni Fabrizio Pasanisi Alberto Catalano Torkjel Manning Sandanger Inger Torhild Gram Guri Skeie Marta Crous-Bou Esther Molina-Montes Pilar Amiano Sandra Milena Colorado-Yohar Eva Ardanaz Isabel Drake Jonas Manjer Ingegerd Johansson Anders Esberg Aurora Perez-Cornago Elisabete Weiderpass Mazda Jenab Heinz Freisling | 2022 | Cancer Communications2022，42，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员